ALIPAY+
15.7.2024 09:33:27 CEST | Business Wire | Press release
In a fiercely contested UEFA EURO 2024™, Dani Olmo (Spain), Harry Kane (England), Cody Gakpo (Netherlands), Georges Mikautadze (Georgia), Ivan Schranz (Slovakia), and Jamal Musiala (Germany) emerged as joint winners of the Alipay+ Top Scorer award. Each player scored three goals during the tournament, showcasing exceptional performances throughout and contributing to a memorable event that concluded with a thrilling final at Berlin's Olympiastadion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714542692/en/
Eric Jing, Chairman and CEO of Ant Group, presents the Alipay+ Top Scorer award to the onsite winning football player Dani Olmo of Spain at UEFA EURO 2024™ (Photo: Business Wire)
“Our warmest congratulations to the six exceptional football players for their stellar performances and for winning the Alipay+ Top Scorer award,” said Eric Jing, Chairman and CEO of Ant Group, while presenting the award at the Berlin Olympiastadion. “Just as these athletes push the boundaries of excellence with strength, ingenuity and teamwork, Alipay+ advances global commerce through digital innovation, empowering people and businesses worldwide.”
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International, is the Official Partner of UEFA EURO 2024™. The Alipay+ Top Scorer trophy, sculpted in the shape of the Chinese character “支” (pronounced zhi, meaning payment as well as support), reflects Alipay+’s dedication to supporting consumers to enjoy seamless cross-border payment and access personalised deals when using their preferred payment methods while traveling abroad.
The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that unit people across the world with passion, ambition, and solidarity. The base of the trophy resembles the ocean, consisting of 24 undulating pieces each inscribed with the names of the participating countries, while the design symbolizes the 24 teams braving the waves at the competition. The ocean also connects continents, which represents how football connects communities across the world similar to Alipay+ connecting global commerce.
Alipay+ has now enabled over 400,000 merchants in Europe, with over 120,000 in the DACH region alone. Among the 15 Alipay+ mobile partners in Germany are Alipay (Chinese mainland), AlipayHK (Hong Kong SAR, China), MPay (Macao SAR, China), Touch ’n Go eWallet and MyPB by Public Bank Berhad (Malaysia), Hipay (Mongolia), GCash (The Philippines), OCBC Digital and Changi Pay (Singapore), TrueMoney (Thailand), Tinaba (Italy), Bluecode (Germany and Austria) and Kakao Pay, Naver Pay and Toss Pay (South Korea).
“With Alipay+ and our global partnerships, global fans and visitors explore Germany, Europe and the bigger world seamlessly using their preferred payment methods. Digital commerce connects communities worldwide just like football,” said Jing. “Looking ahead, we are committed to advancing digital technologies for everyone, supporting a robust, inclusive, and sustainable global digital economy.”
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalization technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714542692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom